December 2017

New Product - Spinraza

Spinraza (nusinersen (heptadecasodium)) is an antisense oligonucleotide specifically designed to treat spinal muscular atrophy (SMA), an autosomal recessive progressive neuromuscular disease, due to mutations in the chromosome 5q. These mutations lead to loss of function of the survival motor neuron 1 (SMN1) gene, resulting in deficiency of SMN protein. The SMN2 gene also produces SMN protein but at low levels. Nusinersen modulates alternate splicing of the SMN2 gene, thus increasing the level of SMN protein in the CNS. Spinraza is indicated for the treatment of 5q SMA. Spinraza solution for intrathecal injection (nusinersen 12 mg) is available in a single 5 mL vial.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au